Effect of autologous platelet-rich plasma transfusion in the treatment of infertile women with thin endometrium and its implications in IVF cycles: a literature review

Abstract

Background

Thin endometrium could be a major contributing factor in decreasing pregnancy rates with in-vitro fertilization. Several treatments have been studied in patients with thin endometrium, like hormonal therapy by GnRH-agonist and estrogen. Additionally, vasoactive measures like aspirin, a mix of pentoxifylline, vitamin E, l-arginine, sildenafil, and intrauterine infusion of a growth factor such as G-CSF, and the recent application of regenerative medicine were reported in previous trials.

Main body of the abstract

We discuss here a new modality for thin endometrium treatment using platelet-rich plasma (PRP) administered as an intrauterine infusion. The purpose of this review is to evaluate the effectiveness of PRP in cases of infertility. All relevant articles addressing the use of PRP, published from January 2000 to September 2018, were reviewed and analyzed. The studies published on the PRP treatment model for thin endometrium in the gynecology field were mainly case series, pilot studies, or case reports.

Conclusion

In the current review, we found that the local administration of PRP is significantly effective in increasing pregnancy rates of infertile women with thin endometrium < 6 mm.

Background

Infertility is a global public health issue; about 13% of the couples suffer from infertility. Implantation failure occurs, despite the effort of fertility clinics in the field of assisted reproductive technology (ART); therefore, high-quality embryo and adequate receptive endometrial growth are required for successful implantation [1]. Pregnancy rates can be increased by increasing the endometrial thickness (ET); the minimum thickness required for implantation is 7 mm [2].

The human endometrium undergoes significant changes during embryo implantation; as its tissues contain receptors for growth factors, cytokines, and lipids that are vital for endometrial and embryonic development; during which the ET affects the rate of successful implantation [3, 4]. Therefore, it has been important for clinicians to make sure that the ET and embryo quality is well measured or treated in case of being suboptimal. Since then, many strategies have been used to increase the ET and to improve its quality for embryo transfer: estrogen, low dose Aspirin, vaginal sildenafil, Pentoxifylline, and granulocyte-colony stimulating factor (G-CSF) intrauterine perfusion. However, these methods cannot improve all cases with a thin endometrium.

Platelet-rich Plasma (PRP) is a new model treatment for thin endometrium. It is a centrifuged fresh human blood containing a high concentration of platelets. PRP is prepared from the patient’s own blood and contains many growth factors and cytokines such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor (TGF) and many other cytokines that can facilitate tissue regeneration and healing. It is found that PRP application improved endometrial regeneration in an animal model with ethanol-induced damaged endometrium [5]. Recently, PRP infusion was applied to humans, especially women who cannot respond to standard treatment.

The objective of this review is to summarize and evaluate the effectiveness of PRP as a treatment of thin endometrium in infertile women and its pivotal role in cases of in vitro fertilization (IVF).

Main text

A narrative review search was done using PubMed, MEDLINE, Scopus, Clinical Key, and Google scholar databases to investigate studies addressing PRP therapy in infertile women with refractory endometrium. We searched the databases from January 2000 to August 2018. We used “Platelet Rich Plasma”, “PRP”, “IVF”, “thin endometrium”, “infertility,” and “Gynecology” as keywords for our search strategy.

The studies found for this review were mainly case reports, case series, letters, and small sample-sized pilot studies. We excluded studies that are performed on animals and studies that are concerned with other clinical uses of PRP. No randomized clinical trials were found on PRP use.

The science of PRP

PRP preparation

Fresh whole blood collected from a peripheral vein is used for the preparation of PRP. Then, it is stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets through the separation of various components of blood [6]. Through activating platelets in PRP, cytokines, and growth factors (GFs) become bioactive and are secreted within 10 min after clotting. These factors include VEGF, TGF, PDGF, and EGF [7]. They can regulate cell migration, attachment, proliferation, and differentiation, and promote extracellular matrix accumulation. There are several methods for PRP preparation, with a difference in the speed and timing of centrifugation [6, 8].

Types of PRP preparation

There are different types of PRP preparations depending on the preparation method, the content of the sample, and the proposed application. The difference in preparations is attributed to the centrifugation time, speed, and anticoagulant use, while the content varies according to the predominant constituent (e.g., leukocytes, platelets, or growth factors) [9]. Four types of preparations can be obtained after centrifugation of whole blood. This classification is based on cell content and fibrin density, as proposed by Ehrenfest et al. [10]. Additionally, it was recommended by a multi-disciplinary consensus committee [11].

Proposed mechanisms of action of PRP

The mechanisms of PRP are not clear; however, laboratory studies have shown that the healing process is enhanced by the high concentration of growth factors in PRP [12]. PRP is superior to the recombinant human growth factor because platelet activation leads to the release of multiple growth factors and differentiation factors. Recently, the fibrin framework present over platelets was found to support the regenerative matrix, leading to the rapid organization of the proper morphological and molecular patterns for wound healing [13, 14].

Implantation failure is considered one of the major challenges facing clinicians in ART despite the significant advances that have been made in this field [15, 16]. Adequate ET is a chief factor for implantation and pregnancy. Women who have persistent thin endometrium often do not go through embryo transfer [17]. Although no definite method was achieved, there are several methods have been described for endometrial preparation. The human endometrial tissue has receptors for growth factors, cytokines, adhesion molecules, and other factors that enhance endometrial and embryonic development [5].

Approaches for thin endometrium management

The thin endometrium may result from several causes or could be idiopathic. For example, the exposure to progesterone therapy for a long time in oral contraceptives may cause thinning of endometrium. Combined oral contraceptives started on menstrual days 1–3 cause a uniformly thin endometrium till in the late luteal phase [18]. In many IVF centers, combined oral contraceptives are used for different purposes and indications.

Here, we will discuss some of the approaches for thin endometrium treatment.

Low dose aspirin

Where “thin” endometrium could result from reduced endometrial blood flow, the use of the vasoactive drug may increase endometrial vascularity with resulting in improvement in endometrial growth. Weckstein et al. studied the effect of low dose aspirin with 28 oocyte donation recipients with a thin endometrium (< 7 mm) [19]. The implantation and clinical pregnancy rates were significantly higher in women who received aspirin compared to those who did not use it, with no improvement in ET. This effect of the low dose aspirin could be due to the improved blood flow observed.

Another study by Hsieh et al. found that the rate of trilaminar endometrium (46.5% vs. 26.2%) and pregnancy rates (18.4% vs. 9.0%) after the administration of (100 mg) aspirin from menstrual day 1 through pregnancy test in clomiphene citrate induced cycles [20].

Pentoxifylline and vitamin E

Pentoxifylline (as a vasodilator) and vitamin E as an antioxidant were used as suggested drugs by Ledee-Bataille et al. [21]. This combination was given to 18 oocyte recipients, who failed to develop a pre-ovulatory ET of at least 6mm following vaginal E2 administration resulted in 72% significant improvement in ET and delivery rates.

Sildenafil

Vaginal sildenafil citrate has been tried in the treatment of patients with RIF. Sildenafil is a phosphodiesterase-5 inhibitor with the vasodilatation effect of nitric oxide produced. The effect of vaginal sildenafil on the ET of infertile patients undergoing IVF treatment have demonstrated improved blood flow in uterine and endometrial growth, with higher implantation and ongoing pregnancy rates after administration vaginal sildenafil. Zinger et al. have reported two infertility patients with Asherman’s syndrome’s who achieved pregnancy after using vaginal sildenafil citrate 25 mg, four times a day for 6–14 days during the first half of their cycles [22].

Estrogen

While there have been many studies regarding estrogen therapy with different administration routes, the vaginal administration of estrogen results in the highest peak of serum estrogen and endometrial level. Therefore, it is considered the preferable way in cases in which the other routes are not effective [23].

Chen et al. have studied the effect of extended estradiol valerate administration during controlled ovarian hyperstimulation cycles and concluded that the average ET in the study group increased from 6.7 to 8.6mm following the estradiol valerate therapy from 14 to 82 days [24]. The pregnancy rate in the study group was increased more than that of the control group (38.5 vs. 4.3%).

GnRH-agonist

The administration of GnRH-agonist improved pregnancy rate in patients who received a mid-luteal injection of a GnRH-agonist. Qublah et al. conducted a controlled randomized study with infertile patients with a thin endometrium (< 7 mm) during an IVF cycle. Patients were randomized between taking a placebo and those who received triptorelin 0.1 mg on ovum pick up day. Significantly higher implantation and pregnancy rates and ET were reported in the treated group compared to the placebo groups. These effects might be explained through the GnRH effect on endometrium [25].

PRP for treatment of thin endometrium

The adequate thickness of the endometrium is probably essential to accomplish a successful pregnancy in ART cycles [26,27,28]. While there is no agreement on the exact value that defines “thin endometrium", El-Toukhy et al. [17] suggested that thin endometrium defined as an ET that cannot reach the threshold for embryo implantation. Moreover, there is no ET value that precludes pregnancy, with previous viable pregnancy reported with ET of 3.7 mm [29]. Several reports have shown a correlation between a “thin endometrium” and low implantation rates [30, 31].

Weissman et al. [32] suggested a minimum ET of 7 mm to maximize pregnancy rates. Richter et al. [31] evaluated the relationship between ET and clinical outcome of IVF in 1294 infertility patients undergoing fresh embryo transfer. They found a higher ET in cycles resulting in pregnancy compared to cycles not resulting in pregnancy. Moreover, clinical pregnancy rates increased from 53% among patients with ET of 59 mm to 77% among patients with ET ≤ 16 mm.

Chang et al. [33] conducted a prospective cohort trial to study the effect of PRP in women with thin endometrium undergoing FET. ET was significantly higher in the PRP group than in the control group (7.65 ± 0.22 mm vs. 6.52 ± 0.31 mm, P < 0.05, respectively) with a lower cancelation rate for the PRP group (P < 0.01). This was reflected by having higher implantation and clinical pregnancy rate in favor of the PRP group (27.94% vs. 11.67%, P < 0.05, respectively). The analysis of the PRP solution showed higher levels of platelet-derived growth factor (PDGF)-AB, PDGF-BB, and transforming growth factor (TGF)-β in comparison to peripheral blood.

These results were on par with the data of Kim et al. [34] that proposed higher implantation, pregnancy, and live birth rates with refractory thin endometrium with PRP administration. Likewise, two additional studies, including one randomized trial, evaluated the impact of PRP in the endometrial growth in cases with poor endometrium [5, 35]. Their data proposed that the use of PRP could significantly improve thin lining. However, this data needs to be confirmed by large randomized and controlled studies. Studies investigated autologous PRP in the state of thin endometrium are summarized in Table 1.

Table 1 Autologous platelet-rich plasma (PRP) infusion in cases of thin endometrium

PRP for refractory endometrium

The endometrium has an important role in achieving optimal outcomes of ART. Endometrial growth after inadequate ovarian stimulation may be insufficient, leading to poor results of IVF cycles. Different strategies have been recommended to improve ET, especially in resistant cases. PRP is a new therapy that has been tried before in those patients (Table 2). Five infertile women, in whom frozen embryo transfer was canceled due to inadequate endometrium, underwent PRP intrauterine infusion after 10 days of estradiol valerate per os. When the endometrium was still detected to be < 7 mm after 72 h, a second intrauterine PRP infusion was performed. Interestingly, endometrial thickness > 7 mm was achieved in all five patients, and they all had a positive pregnancy following the embryo transfer. Four cases experienced ongoing pregnancy, with one case had an early miscarriage from chromosomal abnormalities (45 XO after the analysis of postconceptional products) [5].

Table 2 Autologous platelet-rich plasma (PRP) infusion in cases of refractory endometrium

Colombo et al. [38] evaluated eight patients who underwent PRP treatment. They included women with more than three cancelled cryo-transfers owing to poor endometrial growth (< 6 mm) with a negative hysteroscopic screening for endometrial pathology. After the application of PRP, in seven patients out of eight, the ET was improved more than 6.5 mm with an average of 6.9 mm. A positive test for beta-human chorionic gonadotropin was found in six women. They concluded that PRP administration could improve the multiple implantation failures caused by the inefficient expression of adhesion molecules.

In the same way, Zadehmodarres et al. evaluated 10 patients with a history of canceled cycles due to inadequate endometrial growth (< 7 mm) [2]. At 48 h after the first PRP application, the ET increased and reached more than 7 mm after the second PRP application in all patients. Five patients became pregnant (50%) after embryo transfer with a normal pregnancy in four of them. They concluded that PRP was effective for endometrial growth in infertile women with a thin endometrium.

Molina et al. [36] made a prospective design on 19 infertile patients undergoing High Complexity ART, with a previous history of refractory endometrium and at least one failed IVF attempt and with the exclusion of patients with no history of failed IVF or without refractory endometrium; and the patients aged between 33 and 45 years. An infusion of autologous one cc PRP serum was applied into the uterine cavity, on the tenth day of HRT with estradiol valerate, and again at 72 h of the first administration, using TVS to determine the ET.

After applying the second PRP infusion, all populations in the study achieved ET greater than 9 mm with 14 cases (73.7%) of positive pregnancy and 5 cases of false pregnancy test [36].

Jang et al. [37], in an animal model, tested the role of PRP in endometrial regeneration after ethanol-induced damage. They found that intrauterine infusion of autologous PRP stimulated and accelerated the endometrial regeneration and decreased fibrosis.

PRP for repeated implantation failure

Repeated implantation failure (RIF) is defined as a failure to conceive following several embryo transfers in IVF cycles. Numerous factors are involved in the implantation process as embryo quality, endometrial receptivity, and immunological factors [39]. Several methods have been evaluated before for RIF management, but no agreement on which is most effective. These methods include blastocyst transfer, assisted hatching, endometrial scratching, and immune therapy. Recently, the intrauterine infusion of PRP has been used to promote endometrial growth and receptivity [1, 40].

Nazari et al. [39] included 20 women with a history of RIF to evaluate the effectiveness of PRP in increasing the pregnancy rate in RIF patients. After applying exclusion criteria which were uterine, chromosomal and genetic abnormalities, and hematological, immunological, and hormonal disorders; and inclusion criteria with age below 40 years and body mass index (BMI) below 30 kg/m², they reported that 18 of the 20 participants (90%) became pregnant. Sixteen clinical pregnancies were recorded, and their pregnancies were ongoing at the time of the study, 1 molar pregnancy and 1 miscarriage. Their conclusions were PRP was an effective method in improving pregnancy outcomes in RIF patients [39].

Conclusions

In conclusion, according to the previous studies, we found that the local administration of PRP is significantly effective in increasing pregnancy rates of infertile women with refractory endometrium with ET < 6 mm, therefore increasing endometrial receptivity and vascularity as it contains the growth factors and other cytokines that have positive effects on local tissue repair and endometrial receptivity. There is currently evidence to support the effectiveness of local administration of PRP in successful implantation. Since the PRP is autologous, it is easily obtained, inexpensive, and a safe preparation protocol as it is derived from the patient’s own blood. However, further studies should be conducted with a large number of participants to investigate more protocols in refractory endometrium management.